Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2016-07-25
Target enrollment:
Participant gender:
Summary
This study is to evaluate the antitumor activity (i.e. progression free survival, overall
survival, response rate, etc), safety and quality of life in patient with recurrent or
metastatic gastric cancer during 4-regimen (i.e. SP, FL/Tax, FL/Doc, FOLFOX) based
chemotherapy. In addition, it is to evaluate efficacy and adverse events of anticancer agents
according to the results of pharmacogenetic study.